期刊
NUCLEIC ACIDS RESEARCH
卷 39, 期 2, 页码 623-634出版社
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkq802
关键词
-
资金
- United States Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-98CH10886, W-31-109-Eng-38]
- German Research Foundation (DFG)
- 'Excellence Cluster Cardio-Pulmonary System' (ECCPS)
- Dr -Herbert-Stolzenberg-Stiftung of the Justus-Liebig-University Giessen
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050147] Funding Source: NIH RePORTER
EndA is a membrane-attached surface-exposed DNA-entry nuclease previously known to be required for genetic transformation of Streptococcus pneumoniae. More recent studies have shown that the enzyme also plays an important role during the establishment of invasive infections by degrading extracellular chromatin in the form of neutrophil extracellular traps (NETs), enabling streptococci to overcome the innate immune system in mammals. As a virulence factor, EndA has become an interesting target for future drug design. Here we present the first mutational and biochemical analysis of recombinant forms of EndA produced either in a cell-free expression system or in Escherichia coli. We identify His160 and Asn191 to be essential for catalysis and Asn182 to be required for stability of EndA. The role of His160 as the putative general base in the catalytic mechanism is supported by chemical rescue of the H160A variant of EndA with imidazole added in excess. Our study paves the way for the identification and development of protein or low-molecular-weight inhibitors for EndA in future high-throughput screening assays.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据